At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 224 enrolled
Drug / intervention
Selpercatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Randomized Study to Evaluate the Bioequivalence of Selpercatinib Formulations
In Brief
A Phase 1 clinical trial evaluating Selpercatinib for Healthy. Completed, enrolled 224 participants across 4 sites.
Detailed Summary
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as different formulations. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 56 days including the 28 days of screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartOct 2021
Primary CompletionJul 2022
TodayJul 2026
First PostedOct 22, 2021
Enrollment StartOct 29, 2021
Primary CompletionJul 19, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.7 years ago
Interventions
Selpercatinibdrug
Administered orally